Glioblastoma Multiforme (GBM) Treatment Global Market Size, Share, Analysis And Forecast To 2032

Spread the love

The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2023, provides comprehensive information on the glioblastoma multiforme (GBM) treatment market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Glioblastoma Multiforme (GBM) Treatment Market’s Growth:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

As per The Business Research Company’s Glioblastoma Multiforme (GBM) Treatment Global Market Report 2023, the global glioblastoma multiforme (GBM) treatment market is expected to grow from $2.04 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global glioblastoma multiforme (GBM) treatment market is expected to grow to $3.26 billion in 2027 at a CAGR of 9.7%.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

Advancements in therapies are a key trend gaining popularity in the glioblastoma multiforme (GBM) treatment market. Major companies operating in the market are focused on research and development for therapy innovations to sustain their position in the market. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, launched DELYTACT, the first-ever oncolytic virus-based immunotherapy (Teserpaturev) in collaboration with the Institute of Medical Science, The University of Tokyo to treat malignant glioma. Oncolytic viruses refer to genetically modified viruses that are capable of infecting and specifically replicating in cancer cells, eventually causing cell death without damaging healthy cells to inhibit cell proliferation. The unique features of DELYTACT (Teserpaturev) provide patients with the ability to produce immune-boosting molecules or initiate anti-cancer immunity by triggering the multiple mechanisms of the patient’s immune system and also able to kill the tumor cells that have spread to other parts of the brain.

The glioblastoma multiforme (GBM) treatment market is segmented:

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

North America was the largest region in the glioblastoma multiforme (GBM) treatment market in 2022.

The table of contents in TBRC’s glioblastoma multiforme (GBM) treatment market report includes:
1. Executive Summary
2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics
3. Glioblastoma Multiforme (GBM) Treatment Market Trends And Strategies
4. Glioblastoma Multiforme (GBM) Treatment Market – Macro Economic Scenario
5. Glioblastoma Multiforme (GBM) Treatment Market Size And Growth
…………………………………………………………………………
26. Africa Glioblastoma Multiforme (GBM) Treatment Market
27. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market
29. Glioblastoma Multiforme (GBM) Treatment Market Future Outlook and Potential Analysis
30. Appendix

Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

 

 


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →